Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More…
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone513-762-6690
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.78 billion
Profitability
Miscellaneous
Employees15,707
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Chemed (NYSE:CHE) Frequently Asked Questions
What is Chemed's stock symbol?
Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."
How often does Chemed pay dividends? What is the dividend yield for Chemed?
Chemed announced a quarterly dividend on Friday, August 2nd. Investors of record on Monday, August 12th will be given a dividend of $0.32 per share on Tuesday, September 3rd. This represents a $1.28 annualized dividend and a yield of 0.30%. The ex-dividend date is Friday, August 9th. This is a positive change from Chemed's previous quarterly dividend of $0.30. View Chemed's Dividend History.
How will Chemed's stock buyback program work?
Chemed announced that its Board of Directors has approved a share buyback plan on Wednesday, March 7th 2018, which allows the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board believes its shares are undervalued.
How were Chemed's earnings last quarter?
Chemed Co. (NYSE:CHE) posted its quarterly earnings results on Thursday, July, 25th. The company reported $3.36 earnings per share for the quarter, beating analysts' consensus estimates of $3.09 by $0.27. The firm earned $473.60 million during the quarter, compared to the consensus estimate of $471.72 million. Chemed had a net margin of 10.94% and a return on equity of 35.63%. Chemed's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.81 EPS. View Chemed's Earnings History.
When is Chemed's next earnings date?
What guidance has Chemed issued on next quarter's earnings?
Chemed updated its FY19 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of $13.65-13.85 for the period, compared to the Thomson Reuters consensus estimate of $13.22.
What price target have analysts set for CHE?
3 analysts have issued twelve-month price targets for Chemed's stock. Their predictions range from $405.00 to $500.00. On average, they expect Chemed's stock price to reach $445.00 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Chemed.
What is the consensus analysts' recommendation for Chemed?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemed.
Has Chemed been receiving favorable news coverage?
News coverage about CHE stock has trended somewhat negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chemed earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Chemed.
Are investors shorting Chemed?
Chemed saw a increase in short interest in August. As of August 31st, there was short interest totalling 244,100 shares, an increase of 30.7% from the July 31st total of 186,800 shares. Based on an average daily volume of 111,600 shares, the short-interest ratio is currently 2.2 days. Approximately 1.6% of the company's shares are short sold. View Chemed's Current Options Chain.
Who are some of Chemed's key competitors?
What other stocks do shareholders of Chemed own?
Who are Chemed's key executives?
Chemed's management team includes the folowing people:
- Mr. Kevin J. McNamara, CEO, Pres & Director (Age 65)
- Mr. David P. Williams, Exec. VP & CFO (Age 58)
- Ms. Naomi C. Dallob, VP, Chief Legal Officer & Sec. (Age 65)
- Mr. Spencer S. Lee, Exec. VP (Age 63)
- Mr. Nicholas Michael Westfall, Exec. VP (Age 40)
Who are Chemed's major shareholders?
Chemed's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (12.12%), BlackRock Inc. (10.66%), BlackRock Inc. (10.66%), Acadian Asset Management LLC (3.26%), Riverbridge Partners LLC (2.34%) and Fisher Asset Management LLC (2.19%). Company insiders that own Chemed stock include David Patrick Williams, Donald E Saunders, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Institutional Ownership Trends for Chemed.
Which major investors are selling Chemed stock?
CHE stock was sold by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Riverbridge Partners LLC, Gabelli Funds LLC, Gamco Investors INC. ET AL, First Trust Advisors LP, Renaissance Technologies LLC, Acadian Asset Management LLC and Point72 Asset Management L.P.. Company insiders that have sold Chemed company stock in the last year include David Patrick Williams, Donald E Saunders, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Insider Buying and Selling for Chemed.
Which major investors are buying Chemed stock?
CHE stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Nuveen Asset Management LLC, TimesSquare Capital Management LLC, BlackRock Inc., BlackRock Inc., Teacher Retirement System of Texas, Waddell & Reed Financial Inc. and Bogle Investment Management L P DE. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed.
How do I buy shares of Chemed?
Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chemed's stock price today?
One share of CHE stock can currently be purchased for approximately $426.32.
How big of a company is Chemed?
Chemed has a market capitalization of $6.79 billion and generates $1.78 billion in revenue each year. The company earns $205.54 million in net income (profit) each year or $11.93 on an earnings per share basis. Chemed employs 15,707 workers across the globe.View Additional Information About Chemed.
What is Chemed's official website?
How can I contact Chemed?
Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.
MarketBeat Community Rating for Chemed (NYSE CHE)
MarketBeat's community ratings are surveys of what our community members think about Chemed and other stocks. Vote "Outperform" if you believe CHE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHE will underperform the S&P 500 over the long term. You may vote once every thirty days.
